Last update 12 Dec 2024
VK-2019
Last update 12 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms VK 2019 |
Target |
Mechanism EBNA1 inhibitors(Epstein-Barr nuclear antigen 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with VK-2019Phase 2, Open-label, Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer (NPC) and Other EBV-associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
一种新型小分子EBNA1抑制剂VK-2019用于Epstein-Barr病毒呈阳性鼻咽癌患者的第1/2a期开放标签、多中心临床研究，以及药物代谢动力学及药效学相关性研究
[Translation] Phase 1/2a open-label, multicenter clinical study of a novel small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein-Barr virus-positive nasopharyngeal carcinoma, as well as pharmacokinetic and pharmacodynamic correlation studies
Phase 1/2a Open Label, Multicenter Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer, With Pharmacokinetic and Pharmacodynamic Correlative Studies
100 Clinical Results associated with VK-2019
Login to view more data
100 Translational Medicine associated with VK-2019
Login to view more data
100 Patents (Medical) associated with VK-2019
Login to view more data
1
Literatures (Medical) associated with VK-201901 Feb 2024Biomedical chromatography : BMC
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK‐2019, a selective EBNA1 inhibitor
Article
Author: Davis, Michael T. ; Anders, Nicole M. ; Colevas, A. Dimitrios ; Messick, Troy E. ; Rudek, Michelle A.
Abstract:
EBNA1 is an Epstein Barr virus (EBV) protein expressed in all EBV‐associated cancers. EBNA1 plays a critical role in the replication and maintenance of EBV episomes in latently infected cells. VK‐2019 was developed as a highly specific inhibitor of EBNA1 DNA binding activity and is currently in phase 1 development as a treatment for EBV‐associated carcinomas. A sensitive and reliable method was developed to quantify VK‐2019 in human plasma using liquid chromatography with tandem mass spectrometry to perform detailed pharmacokinetic studies. VK‐2019 was extracted from plasma using protein precipitation with acetonitrile. Separation of VK‐2019, two purported metabolites, and the internal standard, VK‐2019–d6, was achieved with a Zorbax XDB C18 column using a gradient flow over 6 min. VK‐2019 was detected using a SCIEX 4500 triple quadrupole mass spectrometer operating in positive electrospray ionization mode. The assay range was 0.5–500 ng/mL and proved to be accurate and precise. Dilutions of 1:10 were accurately quantified. VK‐2019 was stable in plasma at −70°C for approximately 18 months. The method was applied to assess the total plasma concentrations of VK‐2019 in a patient who received a single and multiple oral daily doses of 120 mg.
100 Deals associated with VK-2019
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Epstein-Barr virus associated Nasopharyngeal Carcinoma | Phase 2 | US | - | 04 Apr 2019 |
| Epstein-Barr virus associated Nasopharyngeal Carcinoma | Phase 2 | US | 04 Apr 2019 | |
| Epstein-Barr virus associated Nasopharyngeal Carcinoma | Phase 2 | CN | 04 Apr 2019 | |
| Epstein-Barr virus associated Nasopharyngeal Carcinoma | Phase 2 | FR | - | 04 Apr 2019 |
| Epstein-Barr virus associated Nasopharyngeal Carcinoma | Phase 2 | FR | 04 Apr 2019 | |
| Epstein-Barr virus associated Nasopharyngeal Carcinoma | Phase 2 | HK | 04 Apr 2019 | |
| Epstein-Barr virus associated Nasopharyngeal Carcinoma | Phase 2 | SG | 04 Apr 2019 | |
| Epstein-Barr Virus Infections | Phase 2 | US | - | 04 Apr 2019 |
| Epstein-Barr Virus Infections | Phase 2 | FR | - | 04 Apr 2019 |
| Nasopharyngeal Neoplasms | Phase 2 | US | 04 Apr 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT04925544 (ASCO2023) Manual  | Phase 2 | 22 | tztprnhiky(stkqoqvxrg) = ngiwodwolb dsiipzygnq (zlhwgupmtj ) View more | Positive | 31 May 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free